Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*BOSTON--(BUSINESS WIRE)--Minerva Biotechnology, a leading nanotechnology, cancer and stem cell development company today announced a major breakthrough in a cancer target that is widely expressed in human cancers. Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study, published today in the journal PLoS ONE (http://www.plosone.org/doi/pone.0002054) focuses on a cell surface receptor, called MUC1, which according to extensive scientific literature is aberrantly expressed on 75% of all human solid tumors – 96% of breast cancers, 47% of prostate cancers, as well as high percentages of ovarian, colorectal, non-small cell lung, and pancreatic cancers. Circulating MUC1 is currently used as a diagnostic marker for breast cancer and over expression also has been shown by many studies to be correlated with poor clinical outcome.Using its unique nanoparticle research platform, Minerva has shown that MUC1 is actually cleaved to a new form, called MUC1* (‘star’). Once cleaved, MUC1* dimerizes with itself and other growth factor receptors through binding of a newly discovered ligand for MUC1*, called NM23. Binding and dimerization then acts to activate the tumor to unregulated cell growth, invasion and metastasis. Blocking MUC1* dimerization and NM23 binding leads to cancer cell death. Minerva has identified both antibody-based and small molecule therapeutics that disable the receptor and block cancer cell growth.This new discovery may also lead to better diagnostics. In collaboration with a leading diagnostic reference lab in California, Minerva has shown that MUC1* is expressed to much higher levels than MUC1 in a variety of human tumor tissues, and in the future could provide both diagnostic and prognostic information on tumor development.About Minerva BiotechnologiesMinerva is a US-headquartered company focused on a next generation novel nanoparticle platform. Minerva enjoys a broad and dominant intellectual property position in the field of nanotechnology with over 100 patents or patent applications filed with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. Minerva has focused squarely on drug discovery and diagnostics for cancer and stem cell treatments and has used its nanotechnology in-house to expedite novel target identification and new drug development. For more information, visit www.MinervaBio.comCopyright © 2008, Minerva Biotechnologies. All rights reserved.ContactsMinerva BiotechnologyCynthia Bamdad, 617-821-8773cbamdad@minervabio.com

Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

Comments

Activity